Antengene Shares Results from Three Trials at 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Nov. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited (Antengene, SEHK: 6996.HK), a leading global biopharmaceutical firm focusing on innovative cancer medicines, announced its participation in the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC 2024) in Houston, USA, from November 6-10, 2024.

Antengene will present data from three significant programs at the event, showcasing advancements in treating B-cell malignancies, autoimmune diseases, and acute myeloid leukemia (AML).

The first presentation will feature ATG-201, a "2+1" CD19 x CD3 T-cell engager (TCE), aimed at B-cell malignancies and related autoimmune conditions. This innovative treatment is designed to bind with CD19+ cells with high affinity, reducing T-cell activation risks and preventing cytokine release syndrome (CRS). The preclinical trials demonstrated that ATG-201 effectively depletes B-cells and combats lymphoma with minimal cytokine release. This research suggests that ATG-201 could provide a therapeutic strategy for both cancer and autoimmune diseases by enabling CD19-dependent T-cell activation and effective B-cell depletion with a lower CRS risk.

The second program to be presented is ATG-107, targeting FLT3 for AML treatment. ATG-107 is another "2+1" CD3-based T-cell engager, crafted to target FLT3, a protein overexpressed in most AML cases. This TCE binds bivalently to FLT3, triggering T-cell activation only upon engagement with FLT3, thus concealing the CD3 binding site until necessary. Preclinical data revealed strong T-cell activation and cytotoxicity against AML cells regardless of FLT3 mutation status. ATG-107 demonstrated powerful in vivo efficacy in AML models, providing a promising option for a wide range of AML patients.

Lastly, Antengene will discuss ATG-106, a "2+1" CDH6-targeted TCE designed to tackle cancers such as ovarian, renal, and thyroid cancers. CDH6, a protein involved in cell adhesion and overexpressed in various cancers, is the target of ATG-106. This TCE activates T-cells only in the presence of CDH6-positive cells, minimizing CRS risks. The preclinical studies underscored ATG-106's strong binding to CDH6+ cells, potent T-cell-dependent cytotoxicity, and significant tumor growth inhibition in ovarian cancer models. These results support ATG-106's potential for further clinical evaluation as an effective anti-tumor treatment.

Antengene's pioneering AnTenGager™ platform underpins these TCEs, providing bivalent binding to disease-specific antigens and a unique CD3 conformational epitope on T-cells. This design reduces systemic CD3 activation and CRS risk, enabling the potential application in autoimmune diseases, hematological malignancies, and solid tumors.

Antengene's extensive pipeline includes several promising TCEs at the IND-enabling stage, such as ATG-201 for B-cell related autoimmune diseases, ATG-102 for AML and chronic myelomonocytic leukemia, ATG-106 for ovarian and kidney cancers, ATG-107 for AML, and ATG-110 for microsatellite stable (MSS) colorectal cancer.

Established in 2017, Antengene has developed a robust oncology pipeline with nine assets at different stages from clinical to commercial. The company has secured 31 investigational new drug (IND) approvals across the U.S. and Asia, and submitted 10 new drug applications (NDAs) in various Asia Pacific markets. Its lead product, XPOVIO® (selinexor), has already been approved in several regions including Mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, Malaysia, Thailand, and Australia.

Antengene remains committed to discovering, developing, and commercializing first-in-class and best-in-class therapies to address unmet medical needs globally, pursuing its mission of "Treating Patients Beyond Borders".